Alto Neuroscience (NYSE:ANRO – Free Report) had its price target trimmed by Robert W. Baird from $32.00 to $10.00 in a research note published on Wednesday, Benzinga reports. The firm currently has an outperform rating on the stock.
ANRO has been the subject of several other reports. Rodman & Renshaw cut Alto Neuroscience from a “buy” rating to a “neutral” rating in a research report on Wednesday. William Blair reaffirmed an “outperform” rating on shares of Alto Neuroscience in a report on Tuesday, September 10th. Finally, Wedbush reissued an “outperform” rating and issued a $29.00 price target on shares of Alto Neuroscience in a research note on Tuesday, September 10th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Alto Neuroscience presently has an average rating of “Moderate Buy” and a consensus price target of $24.40.
View Our Latest Stock Analysis on ANRO
Alto Neuroscience Stock Performance
Alto Neuroscience (NYSE:ANRO – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.07. Sell-side analysts predict that Alto Neuroscience will post -2.63 EPS for the current year.
Hedge Funds Weigh In On Alto Neuroscience
A number of institutional investors have recently bought and sold shares of ANRO. Federated Hermes Inc. lifted its stake in shares of Alto Neuroscience by 33.3% in the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock valued at $128,000 after purchasing an additional 3,000 shares during the last quarter. Bowie Capital Management LLC purchased a new stake in Alto Neuroscience in the 2nd quarter valued at about $462,000. TD Asset Management Inc acquired a new position in Alto Neuroscience in the second quarter valued at about $928,000. Rhumbline Advisers purchased a new position in Alto Neuroscience during the second quarter worth about $113,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Alto Neuroscience during the second quarter valued at about $252,000.
About Alto Neuroscience
Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.
Recommended Stories
- Five stocks we like better than Alto Neuroscience
- Most Volatile Stocks, What Investors Need to Know
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- How to Find Undervalued Stocks
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- What Is WallStreetBets and What Stocks Are They Targeting?
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.